The proper function of the immune system entails multiple regulatory pathways aimed at modulating immunogenic and tolerogenic functions of immune cells. Galectins, a family of carbohydrate-binding proteins, control a variety of biological processes involved in activation, differentiation, trafficking and survival of immune cells. In this review we summarize pioneer work and emerging findings highlighting selected functions of galectins as regulatory checkpoints that control innate and adaptive immune cell programs.
A. Introduction
The immune system is orchestrated by a coordinated network of cells and cytokines that ensures a delicate balance of host responses against microbial infections and tumors, controls sterile inflammation and protects against development of autoimmune responses. Proper execution of immune responses entails recruitment and activation of innate immune cells as well as activation, proliferation and differentiation of effector lymphocytes. However, this system is tightly controlled by a number of different regulatory pathways that counterbalance immune effector functions by repressing innate and adaptive immune programs and avoiding self tissue damage (1) .
Galectins, a family of carbohydrate-binding proteins, have emerged as a new class of soluble molecules capable of stimulating or repressing a number of innate and adaptive immune processes.
These endogenous lectins are synthesized within the cytoplasmic compartment and further exported to the extracellular milieu through mechanisms that are independent of the endoplasmic reticulum (ER) and Golgi apparatus (2) . Interestingly, galectins play extracellular roles through interaction with a variety of glycoconjugates on the cell surface or extracellular matrix but can also function inside the cells by controlling intracellular processes, including autophagy, alternative splicing and intracellular trafficking via protein-protein or protein-glycan interactions (2) .
Members of the galectin family are classified according to their structure into three different groups: 1) 'proto-type' galectins (galectin- 1, 2, 5, 7, 10, 11, 13, 14, 15 and 16) which display one carbohydrate recognition domain (CRD) that can dimerize; 2) 'tandem-repeat' galectins (galectin-4, 6, 8, 9 and 12) which contain two homologous CRDs in tandem in a single polypeptide chain and 3) the chimera-type galectin-3 which uniquely displays a CRD connected to a non-lectin N-terminal region responsible for oligomerization (3) . The multivalent nature of galectin-glycan interactions and the unique biochemical features of these proteins (e.g. sensitivity to oxidative inactivation, requirements for dimerization/ oligomerization and carbohydrate-binding activity) dictate their biological activities. By recognizing poly-lactosamine (LacNAc) residues in complex N-glycans and core 2-O-glycans, galectins can modulate the activation, differentiation, trafficking and survival of immune cells by regulating clustering, internalization, and signaling of relevant glycosylated receptors (2, 4) . In this review we summarize the main biological functions of galectins within innate and adaptive immune compartments and discuss possible mechanisms underlying these effects.
B. Galectin-1 (Gal1)
The immunomodulatory properties of Gal1 were originally inferred by its up-regulated expression in immune privileged sites (e.g. placenta, testis and tumors) and were further evidenced by the ability of this lectin to control pro-inflammatory cytokine synthesis, T-cell survival and immune cell activation (5, 6) . These observations were reinforced by numerous publications describing the ability of exogenous Gal1 to suppress T-cell-mediated autoimmune diseases and the key role of this lectin in tumor-cell evasion of immune responses (6) (7) (8) (9) (10) (11) (12) (13) . Several studies have focused on the immunoregulatory effects of this endogenous lectin in a broad range of innate and adaptive immune functions (6) .
One of the first documented effects of Gal1 was its ability to MINIREVIEW doi: 10.4052/tigg.1740.1SE
(Article for special issue on Galectins) SE98 induce apoptosis of thymocytes and activated T cells (14) (15) (16) . Interestingly, several glycosylated receptors including CD45, CD43 and CD7 have been implicated as counter receptors for Gal1induced cell death (17) (18) (19) . However, despite preferential binding of Gal1 to particular glycosylated receptors, the ability of this lectin to interact with these glycoproteins ultimately depends on the cell's glycosylation machinery, particularly on a set of specific glycosyltransferases acting in concert to generate Gal1-specific glycoepitopes (20) (21) (22) . In this regard, the cytokine milieu responsible for differentiating T helper subsets can also modulate the cell surface glycosylation profile and regulate Gal1 binding and apoptosis. While T helper (Th) 1 and Th17 effector cells express the repertoire of cell surface glycans that are required for Gal1 binding and the subsequent induction of cell death, Th2 cells are resistant to this effect due to the modification of β-galactosides with α2,6-linked sialic acid on cell surface glycoproteins (23) . Thus, the selective elimination of Th1/Th17 cells may contribute to the polarization of the immune response towards the Th2/T regulatory (Treg) profiles observed in experimental models of autoimmunity and cancer. Interestingly, Gal1 activity is not only regulated by the presence or absence of specific glycan ligands, but it also relies on particular physicochemical properties of this protein, including the redox status (Gal1 exhibits an unusual number of 6 cysteine residues in its sequence) and the dimerization equilibrium of this protein. Thus, cell surface glycosylation, together with intrinsic biochemical properties of Gal1, dictate its biological activity and control the fate and function of polarized T cells. However, Gal1 may also trigger regulatory programs through mechanisms that are independent of its pro-apoptotic activity. Particularly, Gal1 promotes the expansion and recruitment of Treg cells in models of pregnancy, parasite infection, autoimmunity and breast cancer, highlighting its central immunoregulatory and pro-resolving activities (12, (24) (25) (26) . Furthermore, Gal1 has been identified as a key effector molecule of the immunosuppressive function of Treg cells (27) . In addition, Gal1 contributes to immunosuppression by directly interfering with T-cell adhesion and cytokine production (28) . Moreover, Gal1 antagonizes TCR-transmitted signals promoting the contraction of the CD8 + T cell compartment (29) , inhibits IFN-γ synthesis in allogeneic T-cell reactions (30) , and promotes IL-10 synthesis on CD4 + T cells (31) . Altogether, these evidences point to a major role of this lectin in re-calibrating T cell responses by controlling the survival, differentiation and activation of these cells ( Fig. 1 ).
Studies aimed at elucidating the role of Gal1 within the B-cell compartment identified the ability of this lectin to form survival niches for developing B cells in the bone marrow. Gal1 produced 
C. Galectin-2 (Gal2)
Gal2 is a member of the prototype group of galectins structurally related to Gal1, nonetheless these galectins differ in their tis-sue distribution (54) . Gal2 is preferentially expressed on epithelial cells of the gastrointestinal tract suggesting a potential role for this lectin in the regulation of mucosal immunity (55) . In this regard, administration of recombinant Gal2 ameliorates clinical manifestations of experimental colitis by impairing viability of lamina propria T cells (55) . Consistently, Gal2 suppress contact allergy by eliminating activated CD8 + T cells (56) (Fig. 1) . The pro-apoptotic function of Gal2 requires recognition of β1 integrin (CD29), but not CD3 or CD7 (55) . Similar to Gal1, Gal2 induces exposure of phosphatidylserine in activated neutrophils, highlighting its potential contribution to clearance of these cells following excessive activation (57) . Interestingly, Gal2 promoted M1 macrophage po- antibodies (80) . Further studies are needed to fully understand the impact of Gal3 and specific glycans on B-cell fate and the consequences of these interactions in physiological and pathological conditions.
In myeloid cells, Gal3 plays multifunctional roles by regulating cellular activation, trafficking, differentiation and survival (2) .
In particular, Gal3 induces neutrophil migration in Leishmania major and Streptococcus pneumoniae infection models (81, 82) . Likewise, this lectin promotes adhesion and increased motility of mast cells on fibronectin-coated plates and is necessary for effective recruitment of DCs to draining lymph nodes after sensing maturation signals (83, 84) . Furthermore, this chimera-type lectin aug- 
E. Galectin-4 (Gal4)
Similar to Gal2, Gal4 displays a tissue-specific distribution being preferentially localized on epithelial cells of the gastrointestinal tract (94, 95) . This tandem repeat-type galectin has also been involved in the regulation of the T-cell viability (Fig. 1) . In particular, Gal4 reduces intestinal inflammation by inducing apoptosis of mucosal T cells and reducing pro-inflammatory cytokine secretion (96) . However, this lectin was also reported to induce IL-6 production in T cells through PKCϕ-dependent pathways, leading to stimulation of an intestinal inflammatory response (97) (Fig. 1 ).
Similar to Gal1 and Gal2, Gal4 was also involved in regulating can also regulate the polarization and differentiation of immune cells. In particular, this endogenous lectin inhibits Th1-and Th17mediated responses in models of arthritis, glomerulonephritis, and encephalomyelitis (108, 112, 113) . Furthermore, this lectin contributes to polarization of macrophages towards an M2 phenotype in samples of advanced melanoma patients (114) . In this regard, recent studies identified a central role of Gal9 as a major ligand of Dectin-1 in macrophages from pancreatic cancer patients endowing these cells with an immunosuppressive pro-tumorigenic phenotype (115) . The immunosuppressive functions of Gal9 were reinforced by additional studies indicating that this lectin is critical for the induction, stability and suppressive activity of Treg cells (113, 116) . The mechanisms underlying these effects involve the interaction of Gal9 with CD44 and the formation of cell surface complexes with TGF-β receptor 1 (117) . Thus, Gal9 fine-tunes immune signaling programs leading to Tim-3-dependent or independent apoptosis of Th1 cells, CD44-mediated expansion of Treg cells and
Dectin-1-dependent modulation of macrophage function (Fig. 1 ).
H. Other Galectins
Although there is still much to be learned on the immunoregulatory activities of other galectins, emerging evidence implicate Gal10, a proto-type member of the family, as an intracellular mediator of the immunosuppressive activity of Treg cells and eosinophils (118, 119) . Moreover, extracellular Gal7 induced T-cell apoptosis whereas intracellularly this lectin controlled proliferation and differentiation of keratinocytes through mechanisms involving the JNK1, miR-203 and p63 signaling pathways (120) (121) (122) . Enforced expression of Gal7 in cancer cells controlled several molecular networks involved in metabolism, survival and immunity (123) .
On the other hand Gal12, a tandem-repeat galectin preferentially expressed in adipose tissue, triggers an inflammatory response through polarization of macrophages towards an M1 profile (124) .
Furthermore, Gal13, Gal14 and Gal16 have been predominantly described in placental tissues, suggesting their potential roles in immune tolerance mechanisms at the maternal-fetal interface (125) .
I. Concluding Remarks
In this review we summarized selected findings on the role of galectins in the regulation of innate and adaptive immune responses and its implications in the development and resolution of autoimmunity, infection, allergy and cancer. Although galectins exert multiple functions on immune cells, some general conclusions can be drawn from many years of research in the field. First, it is clear that some members of this family including Gal1 and Gal9 display predominant immunosuppressive effects, while other members like Gal3 and Gal8 have dual pro-or anti-inflammatory activities.
These variable functions could be associated to intracellular versus extracellular activities of these proteins (126) , different roles of endogenous versus exogenous galectins and subtle differences in glycan-binding preferences of individual members of the family (2, 127) . In this regard, although different galectins share a common structural fold and are defined as β-galactoside binding lectins, individual members of the family display fine specificities for particular substitutions and modifications in the lactosamine core particularly the presence of terminal sialic acid residues (127, 128) .
These glycan structures are differentially regulated in response to pro-or anti-inflammatory stimuli, hypoxic or acidic microenvironments and the metabolic status of target cells. The complexity of this scenario increases as we consider galectin expression pattern and tissue distribution. While some galectins have a wide tissue distribution (e.g. Gal1 and Gal3), others are preferentially distributed on specific cells and tissues (e.g. Gal4, Gal12), suggesting that more than one galectin might be expressed in a given tissue competing for common glycosylated ligands. Additional studies aimed at analyzing specific roles of endogenous galectins in vivo and their possible overlapping activities will contribute to dissect their most important functions in different tissues and their implications in immunopathology. Understanding these pathways will help delineate rational therapies aimed at selectively targeting or reinforcing expression of individual galectins in different pathologic conditions including autoimmunity, allergy, infection and cancer.
